CTOs on the Move


 
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The company is located in Menlo Park, California. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.grail.com
  • 1525 O`Brien Drive
    Menlo Park, CA USA 94025
  • Phone: 650.542.0372

Executives

Name Title Contact Details
Janet G.
Head of Security Profile
Satnam Alag
Senior Vice President of Software Engineering Profile
Angela Lai
Chief Technology Officer Profile

Funding

Grail raised $125M on 12/16/2019
Grail raised $390M on 05/06/2020

Similar Companies

THEON Therapeutics

THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.

CuraSen Therapeutics

CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinson`s Disease, Alzheimer`s Disease and less common neurodegenerative disorders.

Hawaii Bioenergy

Hawaii Bioenergy is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affymax

Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal

Abengoa

Abengoa applies innovative technology solutions for sustainability in the energy and environment sectors, generating electricity from renewable resources, converting biomass into biofuels and producing drinking water from sea water. Abengoa’s business is structured around three activities.